• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Statins reduce the risk of cardiovascular disease in intermediate risk patients: The HOPE-3 trial

byShayna BejaimalandShaidah Deghan, MSc. MD
April 7, 2016
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Statin therapy significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate cardiovascular risk for disease. Specifically, statin therapy was associated with a significant decrease in a composite cardiovascular endpoint consisting of cardiovascular-related death, nonfatal stroke, and nonfatal myocardial infarction (MI).

2. There was no significant difference seen in all-cause mortality.

Evidence Rating Level: 1 (Excellent)

Study Rundown: It is well known that statin therapy in people with elevated cholesterol reduces risk of cardiovascular events, even in those without evidence of CVD. These trials were conducted within a relatively homogenous Caucasian population and all participants had elevated lipid levels. It is unclear if the benefits from statins would encompass ethnically diverse individuals with intermediate risk of CVD but no existing CVD. This trial aimed to determine the efficacy of statins for primary prevention of CVD in individuals with intermediate CVD risk.

Treatment with rosuvastatin resulted in a 25% decrease in risk of cardiovascular events (CV-related death, nonfatal stroke, and nonfatal MI) as compared to placebo in the ethnically diverse, intermediate-risk population without preexisting CVD. There was no significant decrease seen in all-cause mortality. The adverse event of muscle symptoms was higher in the statin group. Strengths of this study include its inclusion of multi-ethnic participants, over multi-national sites to study the efficacy of statins in patients without CVD.

Click to read the study, published today in NEJM

RELATED REPORTS

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin

Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy 

Relevant Reading: Blood-pressure lowering in intermediate-risk persons without cardiovascular disease

In-Depth [randomized controlled trial]: The Heart Outcomes Prevention Evaluation (HOPE)-3 trial was a multicenter, international, double-blind, randomized, placebo-controlled trial was conducted at 228 centres in 21 countries. This trial had a 2-by-2 factorial design studying the effect of rosuvastatin 10 mg daily, candesartan 16 mg/hydrochlorothiazide 12.5 mg daily or a combination of these therapies on the risk of CVD in individuals with intermediate cardiovascular risk. This particular study focused on the statin therapy. Men and women with one CVD risk factor (one of: elevated waist-to-hip ratio, history of low level of HDL, tobacco use, dysglycemia, family history of premature coronary disease or mild renal dysfunction) were included in the trial. All eligible participants underwent a 4-week run-in phase to ensure tolerability and adherence of the medications. Patients were randomized to one of four groups: candesartan/hydrochlorothiazide only, candesartan/hydrochlorothiazide plus rosuvastatin 10 mg, rosuvastatin only or placebo only. Patients were followed regularly for the coprimary outcomes of 1) composite of death from cardiovascular causes, nonfatal stroke, or nonfatal MI 2) the above composite but including resuscitated cardiac arrest, heart failure and revascularization. All-cause mortality was also analyzed as a secondary outcome. Statistical analysis was performed with an intention-to-treat analysis with Cox proportional-hazards models.

From April 2007 to November 2010, 12,705 participants were randomized to the different treatment groups. Median follow-up was 5.6 years. There was a 26.5% decrease in mean LDL-cholesterol in the rosuvastatin group as compared to placebo. The first coprimary outcome occurred significantly less in the rosuvastatin group (3.7% vs. 4.8%; HR 0.76; 95% [CI] 0.64-0.91). There was a significant decrease in the second coprimary outcome in the rosuvastatin group: 4.4% vs. 5.7%, HR 0.75; 95% [CI] 0.64-0.88, p<0.001. A significant increase in muscle symptoms in the statin group was observed (5.8% vs. 4.7%; p=0.005).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: statin
Previous Post

WIC revisions associated with higher diet quality in children

Next Post

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

RelatedReports

Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

June 10, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Cardiology

Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin

October 30, 2024
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Cardiology

Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy 

October 15, 2024
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Cardiology

Statins may improve tolerability of antidepressant therapy

November 17, 2023
Next Post
Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

Infertility treatments not associated with increased short-term cancer risk

Infertility linked to higher birth defect risk

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Paroxetine a good non-hormonal option for hot flashes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
  • Structured exercise intervention improves survival in colon cancer patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.